Curidium was founded in 2001 by Dr. Anne Bruinvels who also developed the Company's proprietary research platform, Homomatrix^®. Curidium's Board of Directors has a strong track record in the pharmaceutical and biotechnology industry.

Based in central London, Curidium has attracted a team experienced in personalized medicine and in the discovery and development of CNS focused drugs. The Company's business is focused on the advancement of new drug development opportunities in partnership with pharmaceutical and biotechnology companies dedicated to developing effective medicines for specific patient subgroups.

Business Evolution

• Curidium has developed a proprietary technology platform, Homomatrix^® a sophisticated, automated data analysis system, to identify patient subgroups distinguished by their gene expression profiles, using datasets of heterogeneous patient populations

• Curidium has identified a blood diagnostic test, called PsychINDx™, to classify patients with schizophrenia and bipolar disorder into four different subgroups with distinct potential disease mechanisms

• Curidium is engaged in licensing CNS drug candidates for development with its personalized medicine approach

• Curidium has attracted an experienced team in personalized medicine and drug development in CNS disorders.